AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00568685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride
Description: Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days
Study NCT01418027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
Study NCT01418027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise
Description: Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
Study NCT01104870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UT-15C
Description: oral
Study NCT01433965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
Study NCT02317042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juno
Description: Juno device set to ST mode with participant's current therapy settings.
Study NCT02317042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juno
Description: Juno device set to AutoEPAP iVAPS mode.
Study NCT02317042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juno
Description: Juno device set to Fixed EPAP iVAPS mode.
Study NCT04495998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brief Motor Scale_portuguese version (BMS_pt)
Description: translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
Study NCT04604366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: it stimulates uterine contractions
Study NCT04604366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: it stimulates uterine contractions
Study NCT03374111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colla corii asini
Description: 15 g Colla corii asini granule daily for 8 weeks
Study NCT03374111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a Simulate Agent of Colla corii asini granule
Description: 15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
Study NCT03660605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
Study NCT04537351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYP-001
Description: The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
Study NCT02790762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
Study NCT02470624 — intervention group
Intervention type: OTHER
Intervention: treatment following current guideline
Study NCT01013480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
Study NCT01062399 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
Study NCT04592328 — intervention group
Intervention type: OTHER
Intervention: Bacterial cultures taken during surgery.
Description: Cultures taken from skin, subcutaneous tissue, surigal materials and surgical gloves at incision and after two hours.
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 2.5 mg/day
Description: During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent RAD001 5 mg/day
Description: During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
Study NCT04032457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase A - olifilcon B with Tangible Coatings
Description: Daily disposable silicone hydrogel contact lens
Study NCT01358305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Blend
Description: Single intake of approximately 20 grams of total protein
Study NCT01358305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Blend
Description: Single intake of approximately 20 grams of total protein
Study NCT03477591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based information
Description: Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
Study NCT03477591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: Patient Decision Aid for prostate cancer screening decision
Study NCT03477591 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham information
Description: Educational information not specific to PSA testing or cancer screening
Study NCT03307824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic glue IfabondTM
Description: Use of the synthetic glue IfabondTM
Study NCT03307824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glue-Free Suture Technique
Description: Suture Technique
Study NCT04465305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: entraped treatment
Description: patients with tarlov cysts treated by entraped and plasty nerve root
Study NCT04465305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasty treatment
Description: patients with tarlov cysts treated by plasty nerve root
Study NCT04465305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasty treatment
Description: patients with tarlov cysts treated by plasty nerve root
Study NCT02369939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: Radiotherapy 55,8 Gy - 59,4 Gy
Study NCT02369939 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Irradiation
Description: Radiotherapy 55,8 Gy - 59,4 Gy
Study NCT02369939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: MMC w1, w5
Study NCT02369939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: MMC w1, w5
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: post-radiation RAD001 10 mg/day
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
Study NCT01062399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: post-radiation temozolomide
Description: Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
Study NCT02778048 — intervention group
Intervention type: OTHER
Intervention: MRI (magnetic resonance imaging)
Description: Assessment of the sphincter
Study NCT02778048 — intervention group
Intervention type: OTHER
Intervention: US (ultra sound)
Description: Assessment of the sphincter
Study NCT02778048 — intervention group
Intervention type: OTHER
Intervention: FLIP (functional lumen imaging probe)
Description: Assessment of the sphincter
Study NCT04032457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - etafilcon A with Tangible Coatings
Description: Daily disposable hydrogel contact lens
Study NCT02328456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SMS and free eye drops
Description: The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
Study NCT03138512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study NCT02778048 — intervention group
Intervention type: OTHER
Intervention: HRAM (high resolution anal manometry)
Description: Assessment of the sphincter
Study NCT00627640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinimide 50-100 mg/day
Description: Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
Study NCT00627640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study NCT04110249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo PAI
Study NCT04110249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Acupoint Electrical Stimulation
Description: Undergo ALTENS
Study NCT01094340 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thalidomide
Description: fixed dose over 8 clinic visits
Study NCT02369939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU w1, w5
Study NCT03952546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline-coupled Bipolar Sealer
Description: The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
Study NCT03952546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar electrocautery
Description: The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
Study NCT00380484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 200µg daily
Study NCT00380484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 5 mg daily
Study NCT00224107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 12 weeks
Study NCT00224107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 12 weeks
Study NCT04020237 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education about particulate matter practice score
Description: For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1) Start air purifier~* 2) Do not go out and make it to the minimum when absolutely necessary~* 3) It is recommended to wear a mask when going out.~* 4) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5) Prepare an inhaler and use it when symptoms get worse.
Study NCT06031467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er, Cr: YSGG laser-assisted non-surgical mechanical therapy
Description: The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
Study NCT06031467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical mechanical therapy
Description: Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
Study NCT00722345 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: review of Canada's Physical Activity Guide for Youth
Description: The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet
Study NCT00722345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise consultation
Description: The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
Study NCT03138512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on specified days
Study NCT03138512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nivolumab placebo
Description: Specified dose on specified days
Study NCT03138512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipilimumab placebo
Description: Specified dose on specified days
Study NCT03138512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab placebo
Description: Specified dose on specified days
Study NCT00180518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
Description: Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients.
Study NCT01554254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: 300mcg/kg/day, subcutaneous injection for up to 28 days
Study NCT03434535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology Intervention
Description: A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
Study NCT02496494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus for maintenance immunosupression in kidney transplant recipients
Study NCT02369939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU w1, w5
Study NCT02369939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 6x deep regional hyperthermia
Study NCT00808756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermentable carbohydrates.
Description: Infant formula enriched with fermentable carbohydrates.
Study NCT00808756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula.
Description: Standard infant formula.
Study NCT02131714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling and exercises
Description: These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
Study NCT02131714 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle counseling
Study NCT01154803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: 1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
Study NCT01154803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powder (MNP)
Description: 2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
Study NCT03413605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Multilevel CBPR Intervention
Description: The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
Study NCT01018823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
Study NCT01018823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
Study NCT02420327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch & placebo capsule
Description: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
Study NCT02420327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch & galantamine capsule
Description: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
Study NCT02420327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch & placebo capsule
Description: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Study NCT02420327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch and galantamine capsule
Description: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
Study NCT02325726 — intervention group
Intervention type: PROCEDURE
Intervention: Renal Resistive Index compared with NephroCheckTM